AKT in cancer: new molecular insights and advances in drug development

di Mundi, Prabhjot S., Sachdev, Jasgit, McCourt, Carolyn, Kalinsky, Kevin
Pubblicato in Br J Clin Pharmacol (2016)

Does Race Affect Outcomes in Triple Negative Breast Cancer?

di Sachdev, Jasgit C., Ahmed, Saira, Mirza, Muhammad M., Farooq, Aamer, Kronish, Lori, Jahanzeb, Mohammad
Pubblicazione 2010

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

di Beg, Muhammad S., Brenner, Andrew J., Sachdev, Jasgit, Borad, Mitesh, Kang, Yoon-Koo, Stoudemire, Jay, Smith, Susan, Bader, Andreas G., Kim, Sinil, Hong, David S.
Pubblicato in Invest New Drugs (2016)

TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (...

di Anders, Carey, Munster, Pamela, Northfelt, Donald, Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Sachdev, Jasgit C
Pubblicato in Neurooncol Adv (2019)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

di Sachdev, Jasgit C., Munster, Pamela, Northfelt, Donald W., Han, Hyo Sook, Ma, Cynthia, Maxwell, Fiona, Wang, Tiffany, Belanger, Bruce, Zhang, Bin, Moore, Yan, Thiagalingam, Arunthathi, Anders, Carey
Pubblicato in Breast Cancer Res Treat (2020)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

di Werner, Theresa L., Sachdev, Jasgit, Swisher, Elizabeth M., Gutierrez, Martin, Kittaneh, Muaiad, Stein, Mark N., Xiong, Hao, Dunbar, Martin, Sullivan, Danielle, Komarnitsky, Philip, McKee, Mark, Tan, Antoinette R.
Pubblicato in Cancer Med (2018)

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

di Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, de Jong, Floris A., Tsimberidou, Apostolia Maria
Pubblicato in Br J Clin Pharmacol (2020)

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

di Lin, Chia-Chi, Arkenau, Hendrik-Tobias, Lu, Sharon, Sachdev, Jasgit, de Castro Carpeño, Javier, Mita, Monica, Dziadziuszko, Rafal, Su, Wu-Chou, Bobilev, Dmitri, Hughes, Lorraine, Chan, Jian, Zhang, Zhi-Yi, Weiss, Glen J.
Pubblicato in Br J Cancer (2019)

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

di de Bono, Johann, Ramanathan, Ramesh K., Mina, Lida, Chugh, Rashmi, Glaspy, John, Rafii, Saeed, Kaye, Stan, Sachdev, Jasgit, Heymach, John, Smith, David C., Henshaw, Joshua W., Herriott, Ashleigh, Patterson, Miranda, Curtin, Nicola J., Byers, Lauren Averett, Wainberg, Zev A.
Pubblicato in Cancer Discov (2017)

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

di Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.
Pubblicato in Br J Cancer (2020)

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

di Kalinsky, Kevin, Hong, Fangxin, McCourt, Carolyn K., Sachdev, Jasgit C., Mitchell, Edith P., Zwiebel, James A., Doyle, L. Austin, McShane, Lisa M., Li, Shuli, Gray, Robert J., Rubinstein, Larry V., Patton, David, Williams, Paul M., Hamilton, Stanley R., Conley, Barbara A., O’Dwyer, Peter J., Harris, Lyndsay N., Arteaga, Carlos L., Chen, Alice P., Flaherty, Keith T.
Pubblicato in JAMA Oncol (2020)

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

di Konstantinopoulos, Panagiotis A., Waggoner, Steven, Vidal, Gregory A., Mita, Monica, Moroney, John W., Holloway, Robert, Van Le, Linda, Sachdev, Jasgit C., Chapman-Davis, Eloise, Colon-Otero, Gerardo, Penson, Richard T., Matulonis, Ursula A., Kim, Young Bae, Moore, Kathleen N., Swisher, Elizabeth M., Färkkilä, Anniina, D’Andrea, Alan, Stringer-Reasor, Erica, Wang, Jing, Buerstatte, Nathan, Arora, Sujata, Graham, Julie R., Bobilev, Dmitri, Dezube, Bruce J., Munster, Pamela
Pubblicato in JAMA Oncol (2019)

Hepatobiliary Cancers: Clinical Practice Guidelines in Oncology™

di Benson, Al B., Abrams, Thomas A., Ben-Josef, Edgar, Bloomston, P. Mark, Botha, Jean F., Clary, Bryan M., Covey, Anne, Curley, Steven A., D'Angelica, Michael I., Davila, Rene, Ensminger, William D., Gibbs, John F., Laheru, Daniel, Malafa, Mokenge P., Marrero, Jorge, Meranze, Steven G., Mulvihill, Sean J., Park, James O., Posey, James A., Sachdev, Jasgit, Salem, Riad, Sigurdson, Elin R., Sofocleous, Constantinos, Vauthey, Jean-Nicolas, Venook, Alan P., Goff, Laura Williams, Yen, Yun, Zhu, Andrew X.
Pubblicato in J Natl Compr Canc Netw (2009)